STOCK TITAN

Inspira Tech - IINNW STOCK NEWS

Welcome to our dedicated page for Inspira Tech news (Ticker: IINNW), a resource for investors and traders seeking the latest updates and insights on Inspira Tech stock.

Overview

Inspira Technologies is a specialty medical device company that focuses on developing breakthrough respiratory support technology. The company is dedicated to addressing the critical challenges associated with respiratory failure and invasive mechanical ventilation, leveraging advanced intravascular oxygenation to provide a safer, non-invasive alternative. With a robust portfolio of proprietary technologies, Inspira Technologies is strategically positioned in the life support and respiratory treatment arena, serving a vital role in transforming clinical approaches in critical care settings.

Technology and Innovation

The core of Inspira Technologies lies in its commitment to scientific innovation. The company has developed the INSPIRA ART system—a groundbreaking solution designed to elevate oxygen saturation levels and reduce carbon dioxide in the blood without the complications of traditional mechanical ventilation. Utilizing sophisticated nano-vesicle technology and advanced real-time monitoring through its HYLA blood sensor, the system offers a nuanced approach to respiratory support. Additionally, the innovative VORTX orbiting oxygenation delivery system represents a paradigm shift by promoting natural blood flow with minimal disruption to blood components.

Clinical Impact and Patient Care

In the realm of critical care, Inspira Technologies addresses a significant clinical need. The devices are engineered to stabilize patients experiencing acute respiratory failure, potentially reducing the need for invasive procedures. By maintaining optimal oxygen levels and mitigating the risk of blood damage typically associated with fiber-based oxygenators, the technology provides clinicians with reliable data and enhanced patient safety. Importantly, the system is designed so that patients can remain awake during treatment, facilitating improved clinical observation and more immediate adjustments based on continuous blood monitoring.

Market Position and Strategic Distribution

Operating within a vast and competitive market, Inspira Technologies targets major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The company’s business model integrates both the sales of core devices and a range of compatible disposable kits, which are designed to generate recurring revenue. Strategic collaborations with established distributors and healthcare institutions, such as distribution agreements with Glo-Med, enhance its market penetration and customer support capabilities. This collaborative approach ensures that leading medical centers and critical care units have ready access to their state-of-the-art respiratory solutions.

Operational Strategy and Industry Leadership

Inspira Technologies is firmly rooted in its scientific and clinical expertise. By consistently advancing its research and development efforts, the company demonstrates a commitment to improving patient outcomes and operational efficiency in critical care environments. The integration of real-time monitoring systems and user-centric design in their products reflects a deep understanding of clinical workflows and the pressing need for safety and efficacy in respiratory treatment procedures. Their operational strategy, which includes rigorous design processes, continual assessment of clinical feedback, and an emphasis on scalable manufacturing partnerships, underlines their authoritative stance in the life support technology sector.

Conclusion

Inspira Technologies exemplifies a blend of medical innovation and operational excellence. Through its breakthrough Augmented Respiration Technology and the incorporation of state-of-the-art monitoring systems, the company not only challenges the conventional use of mechanical ventilators but also redefines the approach towards respiratory support. Its holistic strategy—spanning product development, clinical integration, and strategic distribution—positions Inspira as a distinctive, knowledgeable, and trusted entity in the medical technology landscape.

Rhea-AI Summary
Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) announces partnership with Ennocure MedTech Ltd. to develop bio-electronic technology for bloodstream infection prevention. The company aims to revolutionize life support technology by integrating oxygenation and infection prevention solutions, potentially improving patient outcomes and reducing healthcare costs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) Announces Q3 Financial Results and Progress in Novel Oxygenation Technology Development
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.33%
Tags
-
Rhea-AI Summary
Inspira Technologies has received a grant from the Israeli Innovation Authority for its VORTX Disposable Blood Oxygenation Technology. The VORTX is designed to oxygenate blood and remove carbon dioxide, addressing a $4 billion perfusion disposable market in the medical devices sector. The grant covers 40% of the first-year approved budget of $1 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Inspira Technologies receives additional patent for respiratory medical device, INSPIRA ART500
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Inspira Technologies terminates its at-the-market equity offering program. Operations unaffected by ongoing war.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.25%
Tags
none
-
Rhea-AI Summary
Inspira Technologies signs distribution agreement with CIO MED GROUP, potentially generating $28 million in recurring revenues
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Inspira Technologies unveils INSPIRA ART line at ELSO Conference, including INSPIRA ART100 and ART500 devices. INSPIRA ART500 offers potential breakthrough treatment for severe breathing problems. INSPIRA ART100 estimated to receive FDA clearance in H1 2024. Collaboration with Perfusion Solution for U.S. availability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Inspira Technologies submits INSPIRA ART 100 to FDA, expects clearance in first half of 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
48%
Tags
none
-
Rhea-AI Summary
Inspira Technologies OXY B.H.N. Ltd. announces financial results for Q2 2023. The company had $8.9 million in cash, cash equivalents, and short-term bank deposits as of June 30, 2023. The INSPIRA ART100 is planned for submission to the FDA for clearance. The INSPIRA ART500 is being developed with integrated AI and blood sensor technology. The net loss for the six months ended June 30, 2023, was $5.9 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20%
Tags
Rhea-AI Summary
Inspira Technologies completes Usability Study for INSPIRA ART100 device
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the current stock price of Inspira Tech (IINNW)?

The current stock price of Inspira Tech (IINNW) is $0.2352 as of April 7, 2025.

What is the core focus of Inspira Technologies?

Inspira Technologies specializes in developing innovative respiratory support devices that offer a non-invasive alternative to mechanical ventilation, targeting acute respiratory failure.

How does Inspira Technologies differ from traditional mechanical ventilation?

Their devices utilize proprietary intravascular oxygenation technology and real-time blood monitoring, aiming to maintain adequate oxygen levels without the complications associated with invasive ventilation.

What are the primary technologies developed by the company?

The company’s portfolio includes the INSPIRA ART system, HYLA blood sensor for continuous monitoring, and the VORTX oxygenation delivery system, each designed to optimize patient care.

Which markets does Inspira Technologies serve?

Inspira operates in major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa, focusing on advanced respiratory care.

How does the company enhance patient safety?

The technology is designed to reduce blood trauma and complications by using a non-invasive oxygenation process, allowing patients to remain awake and reducing risks typically seen with mechanical ventilation.

What is the company's approach to distribution and market penetration?

Inspira partners with established distributors and healthcare institutions, such as Glo-Med, to ensure efficient deployment and ongoing support in clinical settings.

What sets Inspira’s technology apart in the critical care industry?

Their innovative approach combines advanced nano-vesicle oxygenation with real-time blood monitoring, offering a flexible and safer option for respiratory support that minimizes invasive procedures.

Where can investors find more detailed information about Inspira Technologies?

Investors can review the company’s detailed disclosures and public filings for comprehensive insights into its technology, operational strategy, and market presence.
Inspira Tech

Nasdaq:IINNW

IINNW Rankings

IINNW Stock Data

24.25M
Medical Devices
Healthcare
Link
Israel
Ra'anana